INTERNEURON's BUCINDOLOL ENTERING NIH/V-A SPONSORED CHF STUDY
INTERNEURON's BUCINDOLOL ENTERING NIH/V-A SPONSORED CHF STUDY involving 3,000 patients set to begin "in late 1994/early 1995," the company said June 22. The Beta-blocker Evaluation of Survival Trial (BEST) will randomize parents to two arms: one receiving placebo plus the current "standard of care" for congestive heart failure (angiotensin-converting enzyme inhibitors when tolerated, diuretics and digoxin), and the other receiving standard care plus bucindolol. The primary endpoint of the study will be mortality. The National Institutes of Health said the study will take five years and will enroll mostly non-Department of Veterans Affairs patients.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth